|
Friedhelm Blobel Ph.D. has been our President Chief Executive Officer and a Director since June 2 2006. Before joining the Company Dr. Blobel served most recently as President Chief Executive Officer and a Director of Gryphon Therapeutics Inc. a South San Francisco based biopharmaceutical company. Prior to joining Gryphon in July 2000 Dr. Blobel spent more than 20 years as an executive with the Hoechst Group and the Boehringer Mannheim Group including many responsibilities in the areas of diabetes and in vitro diagnostics. His roles at these companies included Group President of several product divisions Chief Technology Officer General Manager of a marketing and sales joint venture between Boehringer and Yamanouchi Pharmaceuticals (now Astellas) in Tokyo Japan Senior Vice President of Research & Development Diabetes and Patient Care in Mannheim Germany as well as in Indianapolis Indiana. Dr. Blobel earned his doctorate degree (Dr.rer.nat.; a Ph.D. equivalent) with a dissertation in Biochemistry and Microbiology from the University of Hohenheim Germany and holds an advanced degree in Chemistry from the University of Stuttgart Germany. He serves as a Director of Pelikan Technologies Inc. a Palo Alto based private Biotech company. | 